A new case report describes a perforated duodenal ulcer in a 43-year-old woman using tirzepatide for weight loss. The event occurred about two weeks after she increased her weekly dose from 2.5 milligrams to 5 milligrams.
The report, published September 17, 2026, in Cureus, is the second published case the authors found that links this type of ulcer complication in time with tirzepatide treatment. Two reports cannot establish that the medicine caused either event.
The patient developed severe pain two weeks after increasing the dose
The woman had obesity and anxiety but was otherwise described as healthy. She had used tirzepatide for six weeks and lost 9 kilograms. After four weeks at 2.5 milligrams, she increased to 5 milligrams once weekly.
About two weeks later, she developed sudden severe pain in the upper abdomen and right upper side that spread to her back. A computed tomography scan showed a localized perforation in the third part of the duodenum. A perforation is a hole through the wall of the intestine.
Because the perforation was behind the abdominal lining and she did not have widespread inflammation of the abdominal cavity, the hospital treated her without an operation. She received intravenous fluids, antibiotics, acid-suppressing medicine, a tube through the nose into the stomach, and no food by mouth for three days. She improved and left the hospital on day five.
Missing H. pylori testing prevents a clear explanation
The largest limitation is that the patient was never tested for Helicobacter pylori, a common cause of duodenal ulcers. Antibiotics and acid-suppressing treatment can make later testing less reliable, and the authors say the missed test was a clinical oversight.
That missing result matters because an undetected H. pylori infection could entirely explain the ulcer and perforation. The timing after a tirzepatide dose increase raises a question, but timing alone does not show that one event caused the other.
The report also cannot estimate how often this complication occurs. A case report has no comparison group and may be published precisely because an event is unusual. It cannot tell whether people taking tirzepatide have more duodenal ulcers than similar people who are not taking it.
The report is a safety signal for study, not a new established side effect
Tirzepatide can delay stomach emptying and commonly causes digestive symptoms such as nausea and abdominal discomfort. The authors propose that slower movement through the digestive tract might contribute to ulcer complications, but they describe this as a theory that needs testing.
A follow-up examination with a camera two months later showed normal duodenal tissue and no active disease. The patient was advised to continue acid-suppressing medicine while continuing tirzepatide, according to the report.
The careful takeaway is narrow: this is a rare, serious event reported in one person after a dose increase, with a major alternative cause left untested. It supports further study and careful evaluation of severe abdominal symptoms, but it does not prove a new adverse effect or justify estimating risk from two cases.
Educational information only. This brief is not medical advice. Do not start, stop, or change treatment based on it.
Reporting note
OTN reviewed the linked sources and documents listed above. The article identifies estimates, projections, unresolved questions, and the limits of the evidence.
Editorial standards, corrections, and commerce disclosure · About BariatricPal · About the brief author · Contact BariatricPal